Yesterday Science and Technology Innovation Board With a reputation of “test field” for the reform of China’s capital markets Celebrated its second anniversary of opening.
The summit was guided by People's Government of Xuhui District, Shanghai City and Shanghai United Media Group, sponsored by Jiemian Finance Association| Chinastarmarket.cn, and co-held by Financial Services Office, Xuhui District, Shanghai City. The summit, themed of “Sticking to the Innovation and Navigating the Future”, reviews the development of Science and Technology Innovation Board in the past year, restates the mission of Science and Technology Innovation Board, and enters into a cutting-edge dialog in many areas including the government policy, corporate strategy, technical innovation, and industrial development. On the summit, the Second Anniversary Selection and Award Ceremony for the Science and Technology Innovation Board was held, and Orient Gene (688298) was awarded “2021 Most Valuable Science and Technology Innovation Board Listed Company”.
On the summit, Mr. Fang Xiaoliang, General Manager of Orient Gene, gave a keynote speech for the plenary themed of “Chinese Science and Technology Innovation Go Global”. He said the company was listed on the Science and Technology Innovation Board in early 2020. Besides, by virtue of 15 years of expansive and developmental product portfolio and technology, it has timely and efficiently developed COVID-19 antibodies, antigens, nucleic acid and more than ten detection reagents and been engaged in the global epidemic prevention against COVID-19. The company has realized a huge breakthrough, with efforts and rich gain. Over the past one year since listing, the company's business operation has grown rapidly, and its product quality and performance indicators (net profits, net margin and earnings per share) are among the top of the A-share sub-sectors. The reason why the company rises abruptly based on its accumulated strength is that it has been dedicated to the business for 15 years, also closely related to its being listed into Science and Technology Innovation Board, huge brand influence and capital support from the capital market. In this way, the company has an opportunity to go abroad and go global as an outstanding representative for Chinese technical innovation enterprises.
Technology and Quality will always be the priority in our company, with the market and R&D as the core, Orient Gene adheres to the scientific and technological innovation, break through the current situation, fulfill the mission, go abroad, and contribute to the global medical care undertakings. We will also promote the global leading technical products to further domestic and foreign markets and bear more social responsibilities.